Tascenso ODT, an approved alternative to Gilenya (fingolimod), is now available to multiple sclerosis (MS) patients in the U.S., where it’s being marketed by Cycle Pharmaceuticals. The launch comes about a month after the U.S. Food and Drug Administration approved a 0.5 mg dose of the…
Tascenso ODT
Welcome to “MS News Notes,” where I comment on multiple sclerosis (MS) news stories that caught my eye last week. Here’s a look at what’s been happening: Gilenya alternative The disease-modifying therapy (DMT) Gilenya (fingolimod) has been around since 2010. Now the U.S. Food and Drug Administration has…
The U.S. Food and Drug Administration has approved Tascenso ODT, a bioequivalent formulation of the multiple sclerosis (MS) therapy Gilenya (fingolimod), at a higher patient dose, according to the pharmaceutical company that will market the treatment in the U.S. The newly approved therapy, which is delivered as…